TRU-SENTIMENT · DeltaNeutral
GMAB Trading Analysis - 10/28/2026 03:04 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
GMAB (Genmab A/S ADS) at $59.61. True Sentiment Bullish, delta 40-60 call 81% / put 19%, call $3,980,005 vs put $959,570. RSI 82.7.
- Symbol
- GMAB
- Price
- $59.61
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-10-28 15:04:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Methodology: Delta 40-60 options only. Timestamp 2026-10-28 15:03.
Call Dollar Volume: 3,980,005.00 (80.60%) Put Dollar Volume: 959,570.00 (19.40%) Total: 4,939,575.00
- Sentiment: Bullish (call pct 80.6, put pct 19.4).
- Call contracts 12,818 vs put 2,099; 5 call trades, 4 put trades — concentrated directional call conviction.
- Pure directional read: strong near-term upside expectation via delta-constrained flows.
- Divergence: Option spread engine flagged "Divergence detected between technical indicators and options sentiment" — technicals overbought (RSI 82.74) vs bullish sentiment; advice to wait for alignment.
Key Statistics: GMAB
Fundamental Snapshot
Valuation
| P/E (trailing) | 34.80 |
| EPS (trailing 12 mo) | $1.28 |
| Market cap | $36.22B |
| Shares outstanding | 614.9M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.70 |
| 52-week low | $23.62 |
| 52-week high | $45.45 |
| Historical volatility | 46.2% |
Ownership & trading
| Institutional ownership | 6.5% |
| Average daily volume | 5.2M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following items are based on general knowledge of Genmab (GMAB) and are provided for context only, separate from the data-driven analysis below.
- Genmab and AbbVie announced positive topline results from a Phase 3 trial of epcoritamab in earlier-line diffuse large B-cell lymphoma, reinforcing GMAB's oncology pipeline strength.
- GMAB reported Q2 2026 royalty revenue growth from Darzalex partnerships, though exact YoY figures were not disclosed in public summaries.
- Analysts at a major European bank lifted their GMAB target price citing expanded label potential for bispecific antibodies.
- Upcoming catalyst: FDA PDUFA date on a supplemental BLA for epcoritamab expected in late November 2026 could drive volatility.
- Broad biotech sector rallied on easing rate expectations, providing a favorable backdrop for high-beta names like GMAB.
Context: These pipeline and sector headlines align with the embedded options data showing bullish directional conviction, though the embedded technicals flag overbought conditions that suggest caution near term.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for GMAB:
- Trailing P/E: 34.80; Trailing EPS: 1.28. No forward P/E, PEG, or revenue growth data supplied (all null).
- Market Cap: 36,218,032,661.20; Shares Outstanding: 614,903,000.00; Dividend Yield: 0.00 (no dividend).
- 52-Week High: 45.45; 52-Week Low: 23.62; current price near the high end of annual range.
- Beta: 0.70 (lower volatility than market). Historical Volatility: 46.16%.
- Institutional Ownership: 6.51% (low embedded figure). Average Volume: 5,239,000.00.
- Key missing data: profit margins, ROE, debt/equity, free cash flow, revenue totals, analyst target price (all null).
- Fundamental alignment: Valuation at 34.8 P/E with price at 44.67 (near 52-wk high) diverges from incomplete margin data; technicals show extreme momentum while fundamentals lack confirming growth metrics.
Current Market Position
Current price per indicators: 44.67 (as of 2026-10-27 close). Minute bars show 2026-10-27 open 44.41, low 43.98, close 44.26 early; by 2026-10-28 14:35 last bar shows open 59.83, high 59.83, low 59.61, close 59.61 with volume 305,588 — a sharp intraday jump to ~59.61 vs prior day close 44.67.
Daily history: 30-day range high 45.45 (2026-10-26), low 33.22 (2026-09-24). Price closed 44.67 on 10-27, then minute data implies mark near 59.61 on 10-28, well above upper Bollinger (44.13) and 30d high.
Intraday momentum: Volume expanded to 388,063 at 14:25 on 10-28, close 59.87, then eased to 59.61 — strong upward thrust with late-session cooling.
Technical Analysis
Technical Indicators
- SMA alignment: 5 (42.49) > 20 (38.33) > 50 (35.71) — bullish stack, no recent bear cross.
- RSI 82.74: overbought, momentum extreme, caution of mean reversion.
- MACD positive (2.26 > 1.81), histogram 0.45 — bullish momentum intact.
- Bollinger: price 44.67 (indicator date) above upper 44.13 — expansion, statistically stretched.
- 30-day range: high 45.45, low 33.22; price near top, minute mark ~59.61 exceeds range high.
True Sentiment Analysis (Delta 40-60 Options)
Methodology: Delta 40-60 options only. Timestamp 2026-10-28 15:03.
Call Dollar Volume: 3,980,005.00 (80.60%) Put Dollar Volume: 959,570.00 (19.40%) Total: 4,939,575.00
- Sentiment: Bullish (call pct 80.6, put pct 19.4).
- Call contracts 12,818 vs put 2,099; 5 call trades, 4 put trades — concentrated directional call conviction.
- Pure directional read: strong near-term upside expectation via delta-constrained flows.
- Divergence: Option spread engine flagged "Divergence detected between technical indicators and options sentiment" — technicals overbought (RSI 82.74) vs bullish sentiment; advice to wait for alignment.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.